SCHEMBL7027331

SCHEMBL7027331

COc1cc(CO)c(C2=CCN(C)CC2)c(O)c1C(=O)/C=C/c1ccccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 5/20 0.49
KEAP1 Q14145 3/20 0.42
NFE2L2 Q16236 3/20 0.42
MAOB P27338 2/20 0.41
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
MAOA P21397 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
QDPR P09417 1/20 0.38
CDK4 P11802 2/20 0.38
CCND1 P24385 2/20 0.38
CCNB2 O95067 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL746543 0.91 ABCG2 (0.52) ABCG2KEAP1NFE2L2MAOBMAPT
SCHEMBL20858963 0.90 ABCG2 (0.51) ABCG2KEAP1NFE2L2MAOBMAPT
SCHEMBL13075649 0.89 ABCG2 (0.50) ABCG2KEAP1NFE2L2MAOBMAPT
SCHEMBL7025959 0.89 AR (0.46) MAOBMAPTMEN1ALDH1A1POLB
SCHEMBL7027348 0.88 NPC1 (0.44) NFE2L2MAOBALDH1A1
SCHEMBL7026486 0.88 MAPT (0.53) MAOBMAPTMEN1KMT2AMAOA
SCHEMBL7026784 0.86 ABCB1 (0.49) ABCG2MAOBMAPTMAOANPSR1
SCHEMBL7025976 0.86 ABCB1 (0.51) MAOBMAPTMAOANPSR1
SCHEMBL7027485 0.85 ABCB1 (0.50) ABCG2QDPR
SCHEMBL7027366 0.84 PDPK1 (0.47) ABCG2MAOBMAPTMAOANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER SHANDONG UNIVERSITY (CN) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER CDK6, CDK5, CDK4 ABCG2 2761/4885KEAP1 851/4885NFE2L2 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.